212 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 May 24
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
8:11am
period in 2023, primarily due to increased royalties related to higher AMVUTTRA sales volume, partially offset by one-time favorability attributed
8-K
EX-10.1
ALNY
Alnylam Pharmaceuticals Inc
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
compensation” subject to Section 409A be subject to offset by any other amount unless otherwise permitted by Section 409A.
iv. A termination
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
15 Feb 24
Results of Operations and Financial Condition
8:10am
million from employee option award exercises, offset by our operating loss for the year.
A reconciliation of our GAAP to non-GAAP results for the current
8-K
EX-99.1
emdxc3dzmzk7n3u rf
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
8zajng fs
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
86nga
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
h5flc 4g9ldfvfi
27 Oct 22
Results of Operations and Financial Condition
8:10am
8-K
8jf23afuuh9 c1
16 Sep 22
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-99.2
y16cw
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm
8-K
EX-99.1
r6qitdui zkb
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm
8-K
EX-99.1
utc2arm7
28 Apr 22
Results of Operations and Financial Condition
8:10am